T. Rowe Price Associates, Inc. filed a Schedule 13G with the SEC on November 6, 2026, disclosing beneficial ownership of 33,445,993 shares of Pacific Biosciences of California common stock as of October 31, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Associates, Inc. reported beneficial ownership of 33,445,993 shares of Pacific Biosciences common stock.
  • Percent of class: The reported position represents 10.8% of the outstanding class of common stock.
  • Sole voting power: T. Rowe Price disclosed sole voting power over 33,437,007 shares, with zero shares subject to shared voting power.
  • Sole dispositive power: The filing attributes sole dispositive power over 33,445,993 shares to T. Rowe Price, with no shared dispositive power.
  • T. Rowe Price New Horizons Fund interest: According to the filing, T. Rowe Price New Horizons Fund holds 15,591,500 shares, representing 5.2% of the class, within the aggregate position reported.
  • Triggering date: The event requiring the filing occurred on October 31, 2026, according to the statement.

T. Rowe Price Crosses 10% Threshold in Pacific Biosciences Common Stock

According to the Schedule 13G filed November 6, 2026, T. Rowe Price Associates, Inc., a Maryland-incorporated investment adviser, reported an aggregate beneficial ownership position of 33,445,993 shares of common stock (CUSIP 69404D108) in Pacific Biosciences of California (NASDAQ:PACB), whose principal executive offices are located at 1305 O'Brien Drive, Menlo Park, CA 94025. The filing was triggered by an event dated October 31, 2026, and was signed by Ellen York, Vice President of T. Rowe Price Associates, Inc.

The filing discloses that sole voting power covers 33,437,007 shares while sole dispositive power covers the full 33,445,993 shares. No shared voting or dispositive power was reported. T. Rowe Price disclosed that it does not serve as custodian of client assets, and that the ultimate power to direct receipt of dividends and sale proceeds is vested in its individual and institutional clients. The filing states that any discretionary authority delegated to T. Rowe Price may be revoked in whole or in part at any time.

Within the aggregate position, the filing identifies T. Rowe Price New Horizons Fund as holding 15,591,500 shares, representing 5.2% of the class, and states that the fund has the right to receive or direct dividends and sale proceeds on those shares. T. Rowe Price Associates, Inc. serves as investment adviser to T. Rowe Price New Horizons Fund. The filing further states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

T. Rowe Price Associates, Inc. filed a Schedule 13G reporting beneficial ownership of 33,445,993 shares, or 10.8%, of Pacific Biosciences of California common stock as of October 31, 2026, including 15,591,500 shares held by T. Rowe Price New Horizons Fund.